Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon treatment for chronic hepatitis C]

M Yoshikawa1, H Fukui, H Nakano

  • 13rd Department of Internal Medicine, Nara Medical University.

Rinsho Byori. the Japanese Journal of Clinical Pathology
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Anti-tumor effects of carmofur on human 5-FU resistant cells].

Gan to kagaku ryoho. Cancer & chemotherapy·1999
Same author

Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells.

Gastroenterology·1999
Same author

KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.

Hepatology (Baltimore, Md.)·1999
Same author

Detection of anaphylactic reaction in the percutaneously sensitized mouse using the AW method.

Biological & pharmaceutical bulletin·1999
Same author

Glycyrrhizin inhibits TNF-induced, but not Fas-mediated, apoptosis in the human hepatoblastoma line HepG2.

Biological & pharmaceutical bulletin·1999
Same author

Bileaflet mechanical valve (St. Jude Medical valve) replacement in long-term dialysis patients.

The Annals of thoracic surgery·1999

Interferon (IFN) therapy effectiveness for chronic hepatitis C depends on viral load and liver disease stage. Lower pretreatment hepatitis C virus RNA levels and less advanced liver histology predict better IFN treatment responses.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C remains a significant global health concern.
  • Interferon (IFN) alpha therapy has been a cornerstone treatment for chronic hepatitis C.
  • Predicting treatment response is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To identify key factors influencing patient response to interferon (IFN) alpha therapy in chronic hepatitis C.
  • To correlate pretreatment viral load and liver histology with IFN treatment outcomes.

Main Methods:

  • A cohort of 156 patients with chronic hepatitis C received IFN alpha treatment.
  • Hepatitis C virus (HCV) RNA levels were quantified using competitive polymerase chain reaction (PCR).
  • HCV genotyping and liver histology were assessed to correlate with treatment response (complete, partial, no response).

Related Experiment Videos

Main Results:

  • Lower pretreatment serum HCV-RNA levels were associated with complete or partial responses to IFN therapy.
  • Patients with chronic persistent hepatitis showed better responses compared to those with chronic active hepatitis (CAH) 2A and CAH 2B.
  • Advanced liver histology (CAH 2B) and higher viral loads were linked to resistance to IFN therapy.

Conclusions:

  • Pretreatment viral load and liver disease severity are critical predictors of IFN therapy success in chronic hepatitis C.
  • HCV genotype II was the most prevalent and showed variable response rates.
  • Personalized treatment strategies considering these factors may improve IFN therapy efficacy.